A randomized open‐label trial detected no significant between‐group difference in short‐term symptom response, while a completer analysis found differences in weight change over 12 months.
The first approved norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD demonstrated symptom improvements as early as week 1 in phase 3 trials.
Four-day treatment targeting the prefrontal cortex and cerebellum produced larger reductions in suicidal ideation scores than prefrontal stimulation alone in adolescents with major depressive disorder.
MDSpire News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.